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CLINICAL INVESTIGATION
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Metabolic clearance rate and production rate of calcitriol in uremia.
We have previously demonstrated that while both normal humans and
dogs tightly control serum calcitriol levels after 25(OH)D administra-
tion, anephric humans and 5/6 nephrectomized dogs significantly in-
crease circulating 1 ,25(OH)2D when supraphysiological concentrations
of 25(OH)D are reached in serum. Plasma 1 ,25(OH)2D level is deter-
mined not only by its rate of production but also by its rate of
degradation. To furthet characterize the mechanisms involved in the
responses to 25(OH)D therapy in normal circumstances and in chronic
uremia, we measured metabolic clearance rate (MCR) and production
rate (PR) of 1 ,25(OH)2D in normal dogs and in dogs with moderate and
severe renal failure, at normal and supraphysiological serum concen-
trations of 25(OH)D. Basal MCR in uremic dogs, either with moderate
or with severe renal failure, did not differ significantly from normals (6.7
0.7, 6.8 0.4 and 6.8 0.3 mI/mm, respectively). Oral 25(OH)D
administration for two weeks did not affect MCR either in normal
animals or in both groups of uremic dogs. 25(OH)D treatment did not
affect production rates in normal dogs and in animals with moderate
renal failure (with normal basal values of 1 ,25(OH)2D), but significantly
increased 1,25(OH)2D production from 0.13 0.01 to 0.25 0.04 jsg/
day (P < 0.05) in dogs with severe renal insufficiency. These data
suggest that it is the basal level of l,25(OH)2D which regulates the
synthesis of 1 ,25(OH)2D in response to 25(OH)D administration in
normal and uremië animals.
1,25(OH)2D synthesis is strictly dependent upon an adequate
level of vitamin D [1—3]. However, serum calcitriol levels are
not affected by increased vitamin D uptake either in normal
adults [4, 5] or intact chicks and rats [6]. A previous report from
our laboratory confirmed these findings in normal humans after
oral 25(OH)D administration and also demonstrated a similar
pattern in normal dogs. However, 25(OH)D administration
significantly increased serum 1 ,25(OH)2D concentrations in
anephric humans and 5/6 nephrectomized dogs [71. Thus, the
mechanisms operating to tightly control 1 ,25(OH)2D concentra-
tions after substrate challenge under normal circumstances
appear to be absent or abnormal in chronic uremia. As serum
I ,25(OH)D level is not only determined by its rate of produc-
tion but also by its rate of degradation, we measured metabolic
clearance rate (MCR) and production rate (PR) in normal and
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uremic animals under baseline conditions and after the admin-
istration of 25(OH)D.
Methods
Seven normal mongrel dogs and 12 uremic dogs (5/6 nephrec-
tomy) weighing 16 to 23 kg were studied. Four dogs with
moderate renal failure had a GFR of 17.3 2.4 mllmin and eight
dogs with severe renal failure had a GFR of 9.6 1.7 ml/min. A
diet providing 1.6 g calcium and 1.5 g phosphorus per day was
used to prevent hypercalcemia. Basal studies were performed
three weeks after feeding the dogs the above described diet.
Oral 25(OH)D3, at a dose of 100 zg every other day for two
weeks, was administered to seven normal and eight uremic dogs
(4 with moderate and 4 with severe renal failure). Blood
samples were drawn before the metabolic clearance rate mea-
surements to evaluate PTH, ionized calcium, phosphorus,
creatinine, 25(OH)D and 1 ,25(OH)2D levels. Serum ionized
calcium was measured by an ion specific flow through electrode
(Model SS2O, Orion Research, Inc. Cambridge, Massachusetts,
USA). Serum phosphorus was measured by autoanalyzer II.
(Technicon Instruments, Tarrytown, New York, USA.) A
highly sensitive animoterminal PTH radioimmunoassay was
used to measure PTH levels in dogs [8]. 25(OH)D was measured
with a radio receptor assay using sheep serum as the source of
binding protein after purification of the dog 25(OH)D sample
using a Cl8 Sep Pak column [9]. 1,25(OH)2D was measured
using the method developed by Reinhardt et al [10]. In the
extraction procedure, the amount of 96:4 hexane:isopropanol
was doubled to assure complete elution of 25(OH)D. Metabolic
clearance rates and production rates were measured according
to the method of Seeman et al [11] after a single dose of
[3H]-1,25(OH)2D. 0.8 zCi of l,25-(OH)2[26,27-3H]D3 (130 to
180 Ci/mmol, Amersham, Arlington Heights, Illinois, USA) in 1
ml polypropylene glycol were injected intravenously with rapid
and repetitive rinsing by withdrawal and reinfusion of blood in
the limb leg vein. Serial 5 ml blood samples were drawn at 0.5,
1,2,4,6,8,10,15,20,30,45,60,90,120,240,360,480,600 and
1440 minutes from a neck catheter. Total tritium in 1 ml plasma
from the serial blood samples was measured in a Beckman
Model LS 2800 beta counter (Beckman Instruments, Fullerton,
California, USA). Counts per minute were converted to disin-
tegrations per minute using an efficiency versus H number
regression analysis. Average counting efficiency and counting
error were 28.8% 2.2 and 3.6% 0.1, respectively.
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Table 1. Relevant serum measurements before (basal) and after 25(OH)D treatment in dogs with normal renal function, moderate and severe
renal failure
Normal Moderate Severe
Basal 25(OH)D Basal 25(OH)D Basal 25(OH)D
Creatinine 0.79 0.05 0.77 0.03 2.1 0.2c 2.0 Ø3C 3.0 0.5c 3.1 0.4c
mg/dl
25(OH)D 33.7 3.1 152.4 8.8 43.0 7.2 106.8 35.3 5.3 176.3 I7.Sbe
ng/ml
I,25(OH)2D 24.6 1.4 25.0 1.7 23.4 1.0 24.9 1.0 14.7 l.lc 28.4 0.6
pg/mi
ICa 5.1 0.09 5.2 0.05 5.3 0.06 5.4 0.03 5.4 0.1 5.2 0.35
mg/dl
P 3.1 0.3 2.9 0.2 4.6 1.2 4.6 0.9 6.6 12b 8.5 0.7cc
mg/di
PTH 19.4 3.5 15.5 2.9 50.0 7.8a 37.7 4.6 105.0 l5.6 142.5 28.5cc
pg/mi
a, b and c represent P < 0.05, P < 0.01 and P < 0.001, respectively, for statistical differences from normal (superscript) and from moderately
uremic dogs (subscript).
e and f indicate P < 0.01 and P < 0.001 for statistical differences within experimental groups.
Serum pools were prepared for each time point for assess-
ment of authentic [3H] 1 ,25(OH)2D3. Cold 1 ,25(OH)2D3 was
added to each sample to quantitate recoveries. Samples were
extracted using C18 and Silica Sep Pak according to Reinhardt
et al [10] and the 1 ,25(OH)2D fraction collected was dried under
nitrogen, redis solved in 200 d of 5% isopropanol in methylene
chloride and further purified by using a HPLC Zorbax Sil
column and methylene chloride:isopropanol (19:1) as the sol-
vent system. The fraction coeluting with l,25(OH)2D was
collected and counted. Average recovery after HPLC, effi-
ciency for tritiated 1 ,25(OH)2D counting and counting error
were 80.7 2.3; 47.4 2.8 and 4.7 0.17%, respectively.
Percent of authentic 1 ,25(OH)2D was calculated for each time
point. Total tritium in serial serum samples for each dog was
corrected for the percent of authentic 1 ,25(OH)2D found in the
pool. As la,25-dihydroxyvitamin D3-26,23 lactone (1-alpha-
lactone) coeluted with l,25(OH)2D3 using the HPLC system
described above [12], the contribution of 1-alpha-lactone to the
tritiated 1 ,25(OH)2D3 fraction was checked by an additional
HPLC purification using a Zorbax Sil column and 15% isopro-
panol in hexane at a flow rate of 1.2 mI/mm. Retention time for
l,25(OH)2D and 1-alpha-lactone were 7.5 and 13.3 minutes,
respectively. No detectable amount of tritium eluted in the
1-alpha-lactone fraction at 2, 4, 6, 8, 10 and 24 hours after the
bolus injection of tritiated 1 ,25(OH)2D in any of the experimen-
tal circumstances studied. These results agree with previous
findings that under physiological serum levels of 1 ,25(OH)2D,
l-alpha-lactone appeared to be a minor product of 1 ,25(OH)2D
catabolism [13, 14]. Compartmental analysis of isotope disap-
pearance from plasma was carried out using the program
developed by the Statistical Analysis System Institute [15]. A
three compartment model produced the best fit for the plasma
3H 1,25(OH)2D disappearance curve in 73.5% (25/34) of the
dogs studied. A two compartmental model resulted in the best
fit in the remainder. In all cases, parameters obtained from the
best fit model were used to extrapolate to infinity. The meta-
bolic clearance rate was calculated by dividing the administered
dose by the time integral of the area under the curve extrapo-
lated to infinity. Assuming steady state conditions, production
rate was calculated as the product of the metabolic clearance
Table 2. The effects of 25(OH)D administration on M.C.R. (mI/mm)
in normal dogs and in dogs with moderate and severe renal failure
Normal Moderate Severe
Basal 6.8 0.3 (7) 6.7 0.7 (4) 6.1 0.9 (4)
After 25(OH)D 5.8 0.3 (7) 6.3 0.2 (4) 6.0 0.8 (4)
rate and the plasma concentrations of l,25(OH)2D [16]. Paired
t-test analysis was employed to quantitate statistical differences
before and after treatment within experimental groups and
analysis of variance was used to analyze the differences be-
tween groups.
Results
Table 1 shows serum concentrations of creatinine, 25(OH)D,
1,25(OH)2D, ionized calcium, phosphorus and iPTH in normal
dogs and in dogs with severe and moderate renal failure before
and after oral administration of 100 tg of 25(OH)D every other
day for two weeks. (mean SEM, N = number of animals).
25(OH)D administration significantly increased serum 1,25
(OH)2D levels in dogs with severe renal failure. This treatment
did not result in enhanced concentrations of calcitriol in dogs
with either normal renal function or moderate renal failure.
Although in moderate uremia, serum 25(OH)D concentrations
did not achieve the values observed in normal or severely
uremic animals, previous observations from our laboratory [7]
have demonstrated that this two- to threefold increase in
circulating 25(OH)D was sufficient to significantly increase
serum 1 ,25(OH)2D levels in uremia. No significant differences
between serum levels of ICa, P or iPTH occurred with 25(OH)D
treatment either in normal or uremic animals, suggesting that
these modulators of l-alpha-hydroxylase activity were not
determining the different responses observed.
Metabolic clearance rates and production rates were mea-
sured as described in Methods.
MCR values before and after 25(OH)D administration are
shown i9n Table 2. Basal MCR measurements in normal animals
were in close agreement with those reported by Eastell, [17]
using a primed continuous infusion method in dogs of similar
body weight. Basal MCR in moderate or severe renal failure did
862 Dusso et a!: Calcitriol production and clearance in uremia
pg/mi mi/mm pg/day
not differ significantly from normals. Although oral 25(OH)D
intake appeared to slightly decrease MCR of 1 ,25(OH)2D in
normal animals, analysis of variance showed no significant
differences in the MCR of calcitriol after 25(OH)D therapy
between experimental groups (Table 2).
1 ,25(OH)2D synthesis (PR) was significantly lower than nor-
mal in severely uremic animals. (Normals: 0.24 0.02 pg/day,
N = 7; uremics: 0.11 0.01, N = 8; P < 0.01). This reduced
production determined the significantly lower circulating levels
of the hormone in severe uremia (Fig. 1).
Figure 2 summarizes the PR measurements before and after
25(OH)D treatment in dogs with normal renal function, moder-
ate and severe renal failure.
Basal PR in moderate uremia did not differ from normal.
25(OH)D treatment did not affect significantly PR in normal
animals or in dogs with moderate renal failure. In all four of the
eight severely uremic dogs that received 25(OH)D, PR signifi-
cantly increased. (Paired t-test analysis: P < 0.05).
Clearly, an increase in 1 ,25(OH)2D production after 25(OH)D
administration was observed only when basal serum 1,25
(OH)2D concentrations were significantly lower than normal.
The increased PR after 25(OH)D administration in severe
uremia did not differ significantly from the values observed for
normal and moderately uremic dogs.
Discussion
Previous studies from our laboratory have demonstrated that
serum calcitriol concentrations are not affected by supraphy-
siological 25(OH)D levels in normal adults and in normal dogs.
On the contrary, 5/6 nephrectomized dogs and anephric humans
significantly increased serum 1 ,25(OH)2D after oral administra-
tion of 25(OH)D [7].
Circulating levels of calcitriol depend not only upon its rate of
production but also upon its rate of degradation, thus in an
attempt to clarify the mechanisms determining the diverse
response described above, we measured MCR and PR of
calcitriol in normal and uremic dogs.
MCR measurements for normal and severely uremic animals
at physiological levels of 25(OH)D demonstrated that a reduc-
tion in renal mass did not affect significantly the catabolic rate
of the active metabolite of vitamin D. In humans, no significant
differences in calcitriol half life have been found between
normal and uremic subjects [18]. These studies suggest that
other tissues might be major sites for calcitriol inactivation as
reported by Kumar and DeLuca [19].
In rats, however, there is controversy in the literature with
regaid to the effect of the reduction in renal mass in the MCR of
calcitriol. While no changes in MCR of calcitriol were found by
Taylor et al [20] after unilateral nephrectomy or by Hsu et al
after acute tubular necrosis [21], Hsu et al reported a significant
reduction in MCR in unilaterally nephrectomized rats [22].
Moreover, Hsu et al also found a reduction in MCR of calcitriol
when a uremic state was created in rats with normal renal
function [21].
In dogs with severe renal failure, serum 1 ,25(OH)2D concen-
trations were significantly lower than in normal animals. Met-
abolic clearance rate was not affected by 25(OH)D administra-
tion, thus indicating that the increased circulating levels of
1 ,25(OH)2D after treatment were determined by an enhanced
synthesis of the hormone as shown by PR measurements. These
results imply that changes in serum 1 ,25(OH)2D either in
normal dogs or in dogs with renal failure are controlled by
regulation of calcitriol synthesis.
Although there is consistent evidence that serum 1 ,25(OH)2D
varies in direct proportion with GFR, [23—29), a wider disper-
sion of the data around the regression line is observed at higher
GFR. Studies in patients with early renal failure have shown
that serum levels of vitamin D metabolites vary from normal to
clearly reduced values, suggesting that factor other than GFR
contribute to determining serum 1 ,25(OH)2D concentrations
[291.
The complex regulation of 1 a-hydroxylase by PTH [30—36],
calcium [37—41], phosphorus [42, 43], and l,25(OH)2D [30, 311
itself has been extensively explored in vivo and in vitro. In
patients with variable degree of renal failure no significant
correlations between serum 1 ,25(OH)2D and serum calcium or
PTH were found, suggesting that the stimulatory effect on
1 a-hydroxylase described for PTH in vitro cannot prevent the
progressive decrease in serum calcitriol. However, multiple
regression analysis showed a significant inverse correlation
between 1 ,25(OH)2D and serum phosphorus [27].
In agreement with these reports, our severely uremic dogs
(serum iPTH and P levels were significantly higher than normal)
had significantly impaired 1 ,25(OH)2D synthesis but the poten-
tial to respond to supraphysiological 25(OH)D levels and nor-
malize production. The stimulation of 1 a-hydroxylase after
25(OH)D administration observed in severely uremic dogs and
absent in normal animals cannot be attributed to changes in
serum PTH, ionized calcium or phosphorus levels. Thus, to test
the role of serum 1 ,25(OH)2D concentration in the control of its
own synthesis, we studied dogs with moderate renal insuffi-
ciency (early renal failure) with normal serum levels of
1 ,25(OH)2D.
Basal MCR of l,25(OH)2D was not significantly different
from normal and remained unchanged after 25(OH)D therapy.
Circulating 1 ,25(OH)2D concentrations were not changed by
increased serum 25(OH)D, suggesting that 1,25(OH)2D at phys-
iological levels regulates its own synthesis.
In summary, 1) Severe renal failure does not affect the
metabolic clearance rate of calcitriol. 2) In normal animals, the
20
10
Serum MCR PR
1,25(OH)2D
Fig. 1. Serum levels, metabolic clearance rate and production rate of
calcitriol in normal (, N = 7) and severely uremic (a), N = 8) dogs.
Mean (bar) SEM. **D < 0.01.
Fig. 2. Production rates of calcitriol in dogs
with normal renal function, moderate and
severe renal failure before (B) and after (A)
oral 25(OH)D administration (closed circles).
Mean (horizontal bars) SEM are plotted at
both sides of individual values. Paired t-test
and analysis of variance were used as
A indicated in Methods.
constant levels of 1 ,25(OH)2D after 25(OH)D treatment are not
explained by accelerated catabolism of calcitriol but rather by a
regulated production of the hormone. 3) In moderate renal
insufficiency, MCR and PR of calcitriol are not significantly
different from normal values. 25(OH)D therapy does not affect
serum levels, MCR or PR of 1,25(OH)2D. 4) In severe renal
failure, an impaired 1 ,25(OH)2D production leads to lower than
normal serum concentrations of the hormone. 25(OH)D admin-
istration does not affect MCR but significantly enhances circu-
lating 1 ,25(OH)2D levels by increasing production rate.
In conclusion: Supraphysiological 25(OH)D levels stimulate
1 a-hydroxylase activity only when serum 1 ,25(OH)2D concen-
trations are below normal suggesting that, either in normal or
uremic states, physiological serum levels of l,25(OH)2D regu-
late its own production.
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